These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 25438751

  • 1. In silico classification and prediction of VIP derivatives as VPAC1/ VPAC2 receptor agonists/antagonists.
    Li J, Wang X, Liu H, Li H.
    Comb Chem High Throughput Screen; 2015; 18(1):33-41. PubMed ID: 25438751
    [Abstract] [Full Text] [Related]

  • 2. Gene therapy of Cav1.2 channel with VIP and VIP receptor agonists and antagonists: a novel approach to designing promotility and antimotility agents.
    Shi XZ, Sarna SK.
    Am J Physiol Gastrointest Liver Physiol; 2008 Jul; 295(1):G187-G196. PubMed ID: 18467505
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of vasoactive intestinal peptide-elicited coronary vasodilation in the isolated perfused rat heart.
    Sawmiller DR, Ashtari M, Urueta H, Leschinsky M, Henning RJ.
    Neuropeptides; 2006 Oct; 40(5):349-55. PubMed ID: 17030371
    [Abstract] [Full Text] [Related]

  • 4. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.
    Laburthe M, Couvineau A, Tan V.
    Peptides; 2007 Sep; 28(9):1631-9. PubMed ID: 17574305
    [Abstract] [Full Text] [Related]

  • 5. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D, Anouar Y, Jegou S, Fournier A, Vaudry H.
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [Abstract] [Full Text] [Related]

  • 6. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
    Kojima M, Ito T, Oono T, Hisano T, Igarashi H, Arita Y, Kawabe K, Coy DH, Jensen RT, Nawata H.
    Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
    [Abstract] [Full Text] [Related]

  • 7. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
    Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R, Laburthe M.
    J Biol Chem; 2000 Aug 04; 275(31):24003-12. PubMed ID: 10801840
    [Abstract] [Full Text] [Related]

  • 8. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA, O'Dorisio MS, Cox MO, Lara-Marquez M, Goetzl EJ.
    J Pharmacol Exp Ther; 2003 Aug 04; 306(2):638-45. PubMed ID: 12750439
    [Abstract] [Full Text] [Related]

  • 9. Alterations in the relative abundance of the vasoactive intestinal peptide receptors (VPAC1 and VPAC2) and functions in uterine contractility during inflammation.
    Palus K, Całka J, Jana B.
    Anim Reprod Sci; 2021 Feb 04; 225():106680. PubMed ID: 33388613
    [Abstract] [Full Text] [Related]

  • 10. Stimulatory effect of pituitary adenylate cyclase-activating polypeptide 6-38, M65 and vasoactive intestinal polypeptide 6-28 on trigeminal sensory neurons.
    Sághy É, Payrits M, Helyes Z, Reglődi D, Bánki E, Tóth G, Couvineau A, Szőke É.
    Neuroscience; 2015 Nov 12; 308():144-56. PubMed ID: 26321242
    [Abstract] [Full Text] [Related]

  • 11. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
    Cunha-Reis D, Aidil-Carvalho Mde F, Ribeiro JA.
    Hippocampus; 2014 Nov 12; 24(11):1353-63. PubMed ID: 24935659
    [Abstract] [Full Text] [Related]

  • 12. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
    St Hilaire RC, Murthy SN, Kadowitz PJ, Jeter JR.
    Peptides; 2010 Aug 12; 31(8):1517-22. PubMed ID: 20452385
    [Abstract] [Full Text] [Related]

  • 13. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
    Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.
    Mol Pharmacol; 1999 Dec 12; 56(6):1280-7. PubMed ID: 10570056
    [Abstract] [Full Text] [Related]

  • 14. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
    Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP.
    Arthritis Rheum; 2008 Apr 12; 58(4):1086-95. PubMed ID: 18383383
    [Abstract] [Full Text] [Related]

  • 15. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L, Ahrén B, Edgren G, Degerman E.
    Endocrinology; 2005 Feb 12; 146(2):744-50. PubMed ID: 15514088
    [Abstract] [Full Text] [Related]

  • 16. Role of VPAC2 receptor in monocrotaline-induced pulmonary hypertension in rats.
    Koga M, Mizuno Y, Watanabe I, Kawakami H, Goto T.
    J Appl Physiol (1985); 2014 Aug 15; 117(4):383-91. PubMed ID: 24947028
    [Abstract] [Full Text] [Related]

  • 17. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries.
    Grant S, Lutz EM, McPhaden AR, Wadsworth RM.
    J Cereb Blood Flow Metab; 2006 Jan 15; 26(1):58-67. PubMed ID: 15959462
    [Abstract] [Full Text] [Related]

  • 18. A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
    Dickson L, Aramori I, McCulloch J, Sharkey J, Finlayson K.
    Neuropharmacology; 2006 Nov 15; 51(6):1086-98. PubMed ID: 16930633
    [Abstract] [Full Text] [Related]

  • 19. Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP.
    Laburthe M, Couvineau A.
    Regul Pept; 2002 Oct 15; 108(2-3):165-73. PubMed ID: 12220741
    [Abstract] [Full Text] [Related]

  • 20. Activation of VPAC1 receptors aggravates early atherosclerosis in hypercholesterolemic apolipoprotein E-deficient mice.
    Sheikine Y, Deodato B, Olofsson PS, Söderström LA, Lundberg AM, Bodin I, Rudling M, Theodorsson E, Hansson GK.
    Biochem Biophys Res Commun; 2010 Nov 19; 402(3):471-6. PubMed ID: 20951679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.